Finnish Researchers Discover Genes Inhibiting the Spread of Prostate Cancer
News May 15, 2012
The research team of Professor Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) screened dozens of prostate cancers using gene silencing and discovered mechanisms of that inhibit the spread of cancer cells.
Published in the Journal of Cell Science, the study shows that cancer cell adhesive activity, which is easy to measure in a laboratory setting, is directly linked to the ability of the cancer cells to metastasize.
As a result, screening for regulators of cancer cell activity can lead to the discovery of new candidates for pharmaceutical development.
The study describes dozens of new regulators of cancer cell activity; employing gene silencing mechanisms on two of these regulators (CD9 and MMP8) was found to have a direct impact on the spreading of cancer cells.
In the study, researchers Teijo Pellinen and Juha Rantala from Professor Ivaska's research team utilized the cell spot micro array technology developed by VTT.
The method allows researches to study the impacts of all genes in an entire genome in a single experiment.
The study was published in the Journal of Cell Science, a distinguished publication in the field of cell biology.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Blueprints for Anti-cancer Drugs Identified in Bacterial GenomesNews
Scientists have now brought the family of LNM molecules even closer to clinical testing by “mining” the information stored in bacteria genomes. Their research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.READ MORE
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE